The aim of the project is to develop a technological platform using two model hard-to-soluble molecules, with the potential to develop two innovative products and one service, which have the potential to innovate in the EU and global market, with its improved safety and efficacy profile in relation to existing therapies for dry eye disease. The project includes development from TRL 2 to TRL 8. The project is implemented at NUTS 2 region level, Adriatic Croatia, contributing to objective RSO 1.1.Development and strengthening of research capacities. It is part of the RLV Health and Priority Niche FutureFarma-Pharmaceutical of the Future and contributes to the Smart Specialisation Strategy, the thematic priority area Personalised Health Care and all mandatory Call indicators.